Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2025)

Amylyx Pharmaceuticals has reported Accumulated Expenses over the past 5 years, most recently at $17.9 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $17.9 million for Q4 2025, down 25.22% from a year ago — trailing twelve months through Dec 2025 was $17.9 million (down 25.22% YoY), and the annual figure for FY2025 was $17.9 million, down 25.22%.
  • Accumulated Expenses for Q4 2025 was $17.9 million at Amylyx Pharmaceuticals, down from $19.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for AMLX hit a ceiling of $67.9 million in Q1 2024 and a floor of $3.6 million in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $23.9 million (2024), compared with a mean of $31.0 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 982.18% in 2023 and later plummeted 82.22% in 2025.
  • Amylyx Pharmaceuticals' Accumulated Expenses stood at $13.0 million in 2021, then surged by 194.16% to $38.3 million in 2022, then surged by 50.67% to $57.7 million in 2023, then crashed by 58.51% to $23.9 million in 2024, then dropped by 25.22% to $17.9 million in 2025.
  • The last three reported values for Accumulated Expenses were $17.9 million (Q4 2025), $19.5 million (Q3 2025), and $17.5 million (Q2 2025) per Business Quant data.